OncoMatch/Clinical Trials/NCT06961084
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
Is NCT06961084 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Iodine-124 for thyroid cancer.
Treatment: Iodine-124 — Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.
Check if I qualifyExtracted eligibility criteria
Cancer type
Thyroid Cancer
Prior therapy
Must have received: total thyroidectomy
Undergone total thyroidectomy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify